Oryzon Genomics SA (ORY) — Cash Flow Quality Index

Latest as of June 2023: -2.29x

Oryzon Genomics SA (ORY) has a Cash Flow Quality Index of -2.29x as of June 2023. Operating cash flow of €-2.41 Million is below net income of €1.05 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore ORY operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-2.29x
Operating CF / Net Income

Operating Cash Flow

€-2.41 Million
EUR

Net Income

€1.05 Million
EUR

Data as of

Jun 2023
Most recent filing

Oryzon Genomics SA Cash Flow Quality Index (2014–2014)

Historical Cash Flow Quality Index for Oryzon Genomics SA across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see how efficiently does Oryzon Genomics SA generate cash.

Annual Cash Flow Quality Index for Oryzon Genomics SA (2014–2014)

Year-by-year earnings quality comparison for Oryzon Genomics SA.

Year Quality Index Operating CF (EUR) Net Income YoY Change
2014 1.82x €12.13 Million €6.65 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.